Drug Trial Radar · NCT03144674
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Dec 18, 2017
Primary completion
Jan 15, 2021
Study completion May 29, 2024
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- May 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.
Conditions
- Lymphoma
Interventions
ParsaclisibDrug
Parsaclisib at the protocol-defined dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Based on Lugano Classification CriteriaTime frame: Up to approximately 161 weeks
Locations
86 sites in 12 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham Comprehensive Cancer Center
Birmingham, Alabama
Arizona Oncology Associates
Tempe, Arizona
Torrance Health Association
Redondo Beach, California
Sansum Clinic
Santa Barbara, California
Central Coast Medical Oncology
Santa Maria, California
UCLA Healthcare Hematology-Oncology
Santa Monica, California
St. Joseph Heritage Healthcare
Santa Rosa, California
Innovative Clinical Research Institute
Whittier, California
Loyola University Medical Center
Whittier, California
Valley View Hospital
Glenwood Springs, Colorado
St. Mary'S Hospital Regional Cancer Center
Grand Junction, Colorado
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
Advanced Pharma Cr
Miami, Florida
Boca Raton Clinical Research Medical Inc.
Plantation, Florida
Asclepes Research Centers
Weeki Wachee, Florida
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, Illinois
Rush University Medical Center - Consultants in Hematology
Chicago, Illinois
Clinical Trials of Swla Llc
Lake Charles, Louisiana
University of Michigan Cancer Center
Ann Arbor, Michigan
Henry Ford Health System
Detroit, Michigan
Saint Luke'S Hospital of Kansas City
Kansas City, Missouri
COMPREHENSIVE CANCER CeNTERS OF NEVADA - TWAIN
Las Vegas, Nevada
Clinical Research Alliance
New Hyde Park, New York
Nyu Cancer Institute
New York, New York
Hematology Oncology Associates of Rockland
Nyack, New York
White Plains Hospital
White Plains, New York
Duke University Medical Center
Durham, North Carolina
Gabrail Cancer Center
Canton, Ohio
Gettysburg Cancer Center
Gettysburg, Pennsylvania
Charleston Hematology Oncology Associates Pa
Charleston, South Carolina
Renovatio Clinical
The Woodlands, Texas
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Aou Maggiore Della Carita
Rosario, Argentina
Icon Cancer Care
Auchenflower, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Calvary North Adelaide Hospital
North Adelaide, South Australia, Australia
Cliniques Universitaires Ucl Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Universitaire Ziekenhuis Leuven - Gasthuisberg
Leuven, Belgium
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.